Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters.
about
An Increased Risk of Osteoporosis during Acquired Immunodeficiency SyndromeGlutathione and growth inhibition of Mycobacterium tuberculosis in healthy and HIV infected subjectsThe thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitroPeripheral endothelial dysfunction in heart transplant recipients: possible role of proinflammatory cytokines.Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral ReservoirsShort-term bone loss in HIV-infected premenopausal womenWnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathyThe macrophage in HIV-1 infection: from activation to deactivation?A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection.Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex diseaseCytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infectionVariables that affect assays for plasma cytokines and soluble activation markers.Highly active antiretroviral therapy (HAART) and circulating markers of immune activation: specific effect of HAART on neopterinLevels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures.Comparison of serum and cell-specific cytokines in humansIs There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus?Bone and mineral metabolism in human immunodeficiency virus infection.Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms.HIV-1 gp120-induced TNF-{alpha} production by primary human macrophages is mediated by phosphatidylinositol-3 (PI-3) kinase and mitogen-activated protein (MAP) kinase pathways.PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.Bone mass and mineral metabolism in HIV+ postmenopausal women.Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation.Glial TNFα in the spinal cord regulates neuropathic pain induced by HIV gp120 application in ratsEffects of reticuloendotheliosis virus infection on cytokine production in SPF chickens.MELD score, insulin-like growth factor 1 and cytokines on bone density in end-stage liver disease.Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.Salivary cortisol and soluble tumor necrosis factor-α receptor II responses to multiple experimental modalities of acute painParadoxical exacerbation of psoriasis in AIDS: proposed explanations including the potential roles of substance P and gram-negative bacteria.Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART).The efficiency of acute infection of CD4+ T cells is markedly enhanced in the setting of antigen-specific immune activation.Longitudinal microarray analysis of cell surface antigens on peripheral blood mononuclear cells from HIV+ individuals on highly active antiretroviral therapyProduction of lipopolysaccharide-induced tumour necrosis factor during influenza virus infection in mice coincides with viral replication and respiratory oxidative burst.Adverse bone health among children and adolescents growing up with HIV.Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men.The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.Increased Escherichia coli-induced interleukin-23 production by CD16+ monocytes correlates with systemic immune activation in untreated HIV-1-infected individuals.Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of diseaseCirculating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance.TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?
P2860
Q24791238-35D4437D-A241-476D-A199-11F0E4E2F14FQ25257283-2D80F021-37B2-486D-9180-1BFB9FCEA5EDQ28343837-11D4EE29-41E5-453C-9988-1A311ECD1ED7Q30873807-53EE11DF-D580-4D1B-8AF2-5D844A5EEBC0Q33613493-F596CC24-A51B-49D4-84C3-4C69F5871B08Q33618567-5CDFF2B1-9894-4B2D-AB21-E0AF71A53DDFQ33799421-CE6A358D-E41B-48A8-813E-67BB5089C98EQ33810779-588A2A5E-AE4B-4788-AA98-65607285D926Q33824835-0815ABCF-350B-4A3D-BB85-5810F82C4865Q33970989-58093EB7-7FF6-4BE8-8FAD-4E7185E93A6CQ33997410-8DD018EE-7D30-4478-897A-A03BD0BB5414Q33997552-25551CF1-60BF-425D-B159-71AA021FECDDQ33998654-F95BFD26-D284-4124-90B0-C19CC537CD08Q33999560-3C32E46C-E6B5-4D73-995C-531F773B4635Q33999709-D6BD3A80-237B-446F-94E6-30606251B529Q34074149-5155ABFA-385E-4315-835F-A8AE6F2BA2F9Q34125502-1F303B75-0FD0-4F54-9387-2B0B685AC69DQ34153021-D3CFDC6B-8368-428E-9183-6B11D9A91101Q34284119-13675AA5-4922-4A23-812F-F9C71ECAD0EBQ34440467-CC73218D-0B98-4B80-969C-C155D0CD26DAQ34549590-377F571E-5102-4428-9DF2-B0B1A1D166AFQ35024414-52507FE6-4B7B-4B54-857C-3DD071F25A88Q35043898-247EB706-ED4C-4999-B441-D4272C906F04Q35063688-76F9A48C-57AB-4AE5-94F9-56F82818B801Q35073202-2D1BF72C-A63E-4E57-A36C-C3F1056FE807Q35174818-1FA6C3AF-A432-4918-BCDC-973132D87B8DQ35271085-29542267-33C4-4D57-A30C-19380CEE1E9BQ35605801-482DD933-FDC4-4BCB-95F5-6BC0E43D549FQ35759102-534587A2-D5BB-4A35-A2D7-37F6F6B2417CQ35959017-D82E8A22-CBB0-41DB-82DA-7E05142FD3DFQ36366278-370A6A3A-FFD5-4B9F-B381-78C3588DD6DAQ36512579-C4969566-0987-404D-A8EE-2BBA1F69B7ADQ36627744-CC68ACAE-4287-4612-B83A-17B69DD98086Q37098360-067B1A48-3A99-4656-95B2-FD7EFF4F946DQ37235079-7C31C188-229D-48AB-B32D-E5F18D5CB8DDQ37306090-0C6AE935-ADA8-43D2-AEB4-E31D161E5E80Q37336750-3FF3C0AD-6E62-403D-88FA-A44592021DA3Q37374033-48DB2427-1ED2-4B6F-9078-EBBDA7147129Q37418469-C0B0AB16-898F-4306-B909-52A2D99880F7Q37433321-AB9868CD-9A10-4651-9455-1C0FCE456405
P2860
Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Serum levels of tumor necrosis ...... gic, and virologic parameters.
@en
Serum levels of tumor necrosis ...... gic, and virologic parameters.
@nl
type
label
Serum levels of tumor necrosis ...... gic, and virologic parameters.
@en
Serum levels of tumor necrosis ...... gic, and virologic parameters.
@nl
prefLabel
Serum levels of tumor necrosis ...... gic, and virologic parameters.
@en
Serum levels of tumor necrosis ...... gic, and virologic parameters.
@nl
P2093
P50
P356
P1476
Serum levels of tumor necrosis ...... gic, and virologic parameters.
@en
P2093
P304
P356
10.1093/INFDIS/169.2.420
P407
P577
1994-02-01T00:00:00Z